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Figures E1 to E3 are available
online.doi:10.1016/j.jtcvs.2004.11.032Objective: A follow-up study was performed to assess long-term survival, valve-
related complications, and pregnancy outcomes in young rheumatic women under-
going isolated mitral mechanical replacement. The influence of prosthetic type on
outcomes was also investigated.
Methods: Between 1975 and 2003, 267 isolated mitral mechanical prostheses were
implanted. Follow-up reached 3707.8 patient-years.
Results: Actuarial survival at 1, 5, 10, 15, 20, and 25 years was 97%  0.01%,
90.4%  0.017%, 85.3%  0.023%, 82.3%  0.025%, 71.7%  0.036%, and
70.2%  0.038%, respectively. At multivariate analysis, atrial fibrillation at
follow-up was identified as an independent risk factor for late mortality, whereas left
ventricular ejection fraction at 12 postoperative months proved to be a protective
factor. Freedom from thromboembolism at 1, 5, 10, 15, 20, and 25 years was 98.1%
 0.01%, 94.1% 0.015%, 89.1% 0.021%, 85.9% 0.025%, 81.1% 0.031%,
and 75.3% 0.063%, respectively. Atrial fibrillation and Carbomedics device were
significantly associated with an increase in thromboembolic events. Freedom from
reoperation at 1, 5, 10, 15, 20, and 25 years was 99.2%  0.005%, 95%  0.014%,
91.6%  0.018%, 88.6%  0.022%, and 85.7%  0.041%. Type of prosthesis
(tilting disc) was identified as a predictor of reoperation. At the end of the study, 208
patients were still alive: 94.7% were in New York Heart Association class I or II.
When receiving warfarin therapy, no patient undertaking pregnancy (n  35)
experienced adverse cardiac or valve-related events. Fetal events were significantly
less frequent with a daily warfarin dose less than 5 mg.
Conclusions: Mechanical devices provided excellent performance, safety, and du-
rability. The prognostic role of left ventricular function and atrial fibrillation
overwhelmed any differences that might exist between different prosthetic designs.
Pregnancies entail virtually no maternal risk and predictable fetal complications.
T he optimal surgical strategy for rheumatic mitral valve disease is still highlydebated.1-3 The peculiar management issues relating to the childbearingpotential of young women, a highly represented patient subset, add to the
intrinsic challenge of dealing with this topic.4
The primary purpose of this article was to provide long-term follow-up data of
isolated mitral valve replacement with mechanical prostheses over a 27-year period
in a young rheumatic population. Maternal and fetal outcomes of pregnancies were
also investigated. The secondary aim was to evaluate the influence of the type of
replacement device on outcomes.
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Patient Population
Between January 1975 and December 2002, 1567 patients were
referred to the Department of Cardiothoracic and Respiratory
Sciences of the Second University of Naples for mitral rheumatic
disease. Reparative procedures were performed in 905 patients
(57.7%). The study population included young female patients
(defined as 15 to 40 years old) who underwent isolated mitral valve
replacement with mechanical prosthesis (n  267).
Operative Technique, Type of Prosthesis, and
Anticoagulation Management
Prosthesis implantation was performed by using the same princi-
ples of technique throughout the study period. All the prostheses
were implanted at the supra-annular level by using Tevdek 2-0
(Genzyme Surgical Products, Tucker, Ga) mattress sutures. Given
the severe involvement of the subvalvular apparatus, chordal pres-
ervation in this subgroup was feasible in only 12 cases (4.45%).
Biological prostheses were not favored in this patient subset by
policy. The choice of prosthetic model was made on the basis of
availability, surgeon preference, or both. Seventy-three patients
received a caged ball, 133 a tilting disc, and 61 a bileaflet pros-
thesis. Anticoagulation with warfarin was begun on the second
postoperative day in all patients. The targeted international nor-
malized ratio (INR) ranged from 3.0 to 4.0 for patients with caged
ball or tilting disc prostheses and from 2.5 to 3.5 for those with
bileaflet valves. Prophylaxis included aspirin 100 mg/d in 79.4%
of the patients receiving a caged ball prosthesis. The adequacy of
the anticoagulation level was followed up in our Anticoagulation
Outpatient Clinic, and doses of warfarin were adjusted according
to INR assessments performed at least monthly.
Management of Pregnant Women
Our anticoagulation protocol was based on sodium warfarin ad-
ministration. Only 2 patients, after general practitioner counseling,
preferred heparin treatment (unfractionated subcutaneous heparin).
As previously described,4,5 cesarean delivery was scheduled be-
fore the end of the 37th gestational week. Warfarin therapy was
discontinued only 2 days before delivery and was restarted 1 day
after delivery: during that period, heparin was not administered,
and INR was checked daily. Throughout pregnancy, INR was
estimated weekly at our outpatient clinic and recorded along with
prescribed warfarin doses. Echocardiographic follow-up was per-
formed monthly, and ultrasound evaluations of the fetus were
performed at the third, fifth, and eighth months. Neonates under-
went clinical examination soon after birth and then at 4 and 12
months to ascertain or exclude the diagnosis of warfarin
embryopathy.
Follow-up and Statistical Analysis
Data on patients undergoing valve replacement at the Department
of Cardio-Thoracic and Respiratory Sciences were entered into a
data chart archive. Data regarding hospitalization were obtained
from hospital records. Patients were followed up at our outpatient
clinic 15 days, 1 month, 12 months, and then yearly after surgery.
On each visit, patients underwent physical examination, laboratory
tests, and electrocardiogram. The first follow-up echocardio-
graphic evaluation was performed at our institution 6 months after
14 The Journal of Thoracic and Cardiovascular Surgery ● July 2surgery. Questionnaires were sent to the general practitioners of all
patients not seen at the outpatient clinic. Follow-up was completed
with phone interviews to either the patients or relatives if data were
missing. All the available follow-up data were entered into a
computerized database. The guidelines of The American Associ-
ation for Thoracic Surgery and The Society of Thoracic Surgeons
were used for reporting mortality, morbidity, and valve-related
complications.6 As to pregnancy outcomes, main end points were
maternal cardiac events (cardiac decompensation, valve thrombo-
sis, and thromboembolism) and the occurrence of spontaneous
abortion, stillbirth, or embryopathy.
SPSS software (version 10.1; SPSS Inc, Chicago, Ill) was used
for statistical analysis. Data were expressed as mean  SD or
counts and percentages when appropriate. Differences in categor-
ical variables were compared by means of the 2 Pearson test or
Fisher exact test. Continuous variables were analyzed with 2-tailed
Student t tests. Nonparametric tests were used when necessary.
With regard to survival, we considered the patient as a statistical
unit, whereas in the analysis of valve-related events we followed
the fate of the implanted mechanical prostheses: in case of reop-
eration with valve prosthesis replacement, the follow-up was trun-
cated at the time of reoperation. Incidences of postoperative events
are presented as absolute frequencies and linearized rates (percent-
age per patient-year) and were compared by using the likelihood
ratio test. Actuarial survival, freedom from reoperation, and throm-
boembolism were calculated with the time–life table method.
Comparisons between groups were performed with the nonpara-
metric Wilcoxon-Gehan pairwise test. The Cox proportional haz-
ards model (multivariate forward stepwise regression) was used to
determine the relative risk of late death and valve-related compli-
cations (thromboembolism and reoperation) associated with peri-
operative variables. All variables tested at univariate analysis were
also included in this analysis (Appendix 1). Predictive factors for
poor pregnancy outcome were assessed in univariate and multi-
variate analyses of the following variables: patient age, prosthetic
model, average INR, and average warfarin daily dose. Units of
analysis were pregnancies rather than women because the focus
was on the effect on the fetus of drug assumption. However,
because pregnancies occurring in the same woman share some
common risk factors, we analyzed differences between first and
subsequent pregnancies, and eventually we adjusted for it in mul-
tivariate analysis. These analyses were performed by S-Plus soft-
ware (S-PLUS 2000; MathSoft, Inc, Cambridge, Mass). The effect
of drug assumption on pregnancy outcome after adjustment by
order of pregnancy (first or subsequent) was evaluated by the exact
logistic regression model with LogXact software to account for the
small sample size (LogXact-Turbo; CYTEL Software Corporation,
Cambridge, Mass).
Results
Baseline characteristics and operative variables are summa-
rized in Table 1.
Hospital (30-Day) Mortality
Overall 30-day mortality was 1.12% (3 patients). Causes of
death were cardiogenic shock in 2 cases and cardiac rupture
in 1.
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No patient was lost to follow-up: 56.1% patients were seen
every year, and in the other 38.3%, yearly data from out-
patient visits, general practitioner questionnaires, or phone
interviews were available. For the remaining 5.6% of the
population, the information was updated to February 2003,
although data were not available for each year. The cumu-
lative follow-up was 3707.8 patient-years, ranging from 0.1
to 27.1 years (mean, 4.04 7.29 years; median, 15.9 years).
Bileaflet devices had a significantly shorter observation
period (P  .001). There were 56 (21.2%) late deaths. Table
2 summarizes causes of death. Long-term actuarial survival
at 1, 5, 10, 15, 20, and 25 years was 97%  0.01%, 90.4%
 0.017%, 85.3%  0.023%, 82.3%  0.025%, 71.7% 
0.036%, and 70.2%  0.038%, respectively (Figure E1).
TABLE 1. Patient population data and follow-up time peri
Variable CB (n  73)
Age (y) 31.1  7.03
Valvular disease
Stenosis 29 (39.7)
Mixed 44 (60.3)
Preoperative NYHA class*
I-II 60 (82.2)
III-IV 13 (17.8)
Preoperative AF† 43 (58.9)
Previous open mitral commissurotomy‡ 1 (1.4)
Emergency 3 (4.2)
Operation era
1975-1980 29 (39.7)
1981-1985 36 (49.3)
1986-1990 6 (8.2)
1991-1995 1 (1.4)
1996-2002 1 (1.4)
Mean follow-up, y (median) 17.18  7.21 (18.5)
Cumulative patient-year 1220.1
Data are mean  SD unless otherwise noted. Categorical data are presen
New York Heart Association; AF, atrial fibrillation. *P  .001; †P  .016;
TABLE 2. Late mortality
Variable 1 y 5 y
No. deaths 8 21
Actuarial survival (mean  SD) 97  0.01 90.4  0.017
Cause of death
Cardiac
Noncardiac
Valve related
Ascertained
Sudden unexplained
Non–valve related
Total 56/264 (2
The Journal of ThoracValve-related and non–valve-related events are reported in
Table 3. Table 4 shows the variables associated in univariate
analysis with significantly higher mortality. At multivariate
analysis, chronic atrial fibrillation was identified as an in-
dependent risk factor for late mortality; left ventricular
ejection fraction at 12 postoperative months proved to be a
protective factor (Table 5). When plotting long-term sur-
vival according to the type of replacement device implanted,
no statistically significant difference emerged (P  .34).
Complications
There was no primary mechanical dysfunction. Eighteen
patients (6.8%) experienced obstructive valve thrombosis.
One died during echocardiography examination at the time
of hospital readmission, 3 patients were treated with throm-
TD (n  133) BL (n  61) Total (n  267)
30.8  6.25 32.8  5.95 31.4  6.4
68 (51.1) 28 (45.9) 125 (46.8%)
65 (48.9) 33 (54.1) 142 (53.2%)
43 (32.3) 42 (68.9) 145 (54.3%)
90 (67.7) 19 (31.1) 122 (45.7%)
78 (58.6) 23 (37.7) 138 (51.7%)
11 (8.3) 1 (1.6) 13 (4.9%)
6 (4.5) 3 (4.8) 12 (4.5)
18 (13.5) — 47 (17.6%)
55 (41.4) 1 (1.6) 92 (34.5%)
54 (40.6) 6 (9.8) 66 (24.7%)
6 (4.5) 24 (39.3) 31 (11.6%)
— 30 (49.2) 31 (11.6%)
15.6  6.18 (16.5) 6.94  4.5 (6.2) 14.04  7.29 (15.9)
2063.8 423.9 3707.8
: conts (percentages). BL, Bileaflet; CB, caged ball; TD, tilting disc; NYHA,
.035.
10 y 15 y 20 y 25 y
36 42 55 56
5.3  0.023 82.3  0.025 71.7  0.036 70.2  0.038
) Cumulative % patient/year
5.7) 1.3
4.3) 0.2
4.6) 0.67
1.4) 0.32
3.2) 0.35
5.4) 0.33ods
ted as8
n (%
48 (8
8 (1
25 (4
12 (2
13 (2
31 (51.2) 1.5
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atrial fibrillation in the follow-up period; †introduced in multivariate analysis a
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CDbolysis (2 deaths), and the remaining patients underwent
reoperation (2 deaths). A total of 35 thromboembolic events
occurred in this series: 21 (60%) were major events that led
to permanent functional impairment or death, and 14 (40%)
were minor (almost all transient or reversible ischemic
attacks). Freedom from thromboembolism at 1, 5, 10, 15,
20, and 25 years was 98.1%  0.01%, 94.1%  0.015%,
89.1%  0.021%, 85.9%  0.025%, 81.1%  0.031%, and
75.3%  0.063%, respectively, with a linearized rate of
1.06% patients per year. When we reviewed the anticoag-
ulant status of patients who experienced thromboembolic
events, it seemed that 5.7% were inadequately anticoagu-
lated. The rhythm at the time of the events was atrial
fibrillation in 88.5% and normal sinus rhythm in 11.5% of
cases. Stratifying freedom from thromboembolism accord-
ing to replacement device, significantly worse outcomes
were detected in patients receiving a bileaflet device (Figure
E2).
Eight of 11 thromboembolic events in the bileaflet group
were detected in patients who underwent mitral valve re-
placement with a Carbomedics device. Risk factor analysis
revealed atrial fibrillation as the strongest predictor of
thromboembolism; at the final step of the regression model,
implying atrial fibrillation as a constant, the Carbomedics
device emerged as a significant covariate in the equation
(Table 5). Three patients, all in the caged ball group, expe-
rienced major nonfatal bleeding events (all gastrointestinal).
mboembolism, and reoperation in univariate analysis
omboembolism P value Reoperation P value
.35 .39
18 (14.5%) 12 (9.7%)
17 (12.1%) 16 (11.4%)
.02 .01
1 (7.7%) 0 (0%)
34 (13.5%) 28 (11.1%)
.181 .028
5 (11.1%) 3 (6.7%)
11 (12%) 16 (17.4%)
9 (13.6%) 8 (12.1%)
8 (26.7%) 0 (0%)
2 (6.5%) 1 (3.2%)
.49 .01
8 (11.3%) 1 (1.4%)
16 (12.1%) 26 (19.7%)
11 (18%) 1 (1.6%)
.016 .20
29 (16.7%) 21 (12.1%)
6 (6.7%) 7 (7.8%)
s No Yes No
8 55  7 .54 53.6  9 54.9  7 .37
ejection fraction; OMC, open mitral commissurotomy. *Defined as chronicTABLE 3. Follow-up events
Variable n (%)
Cumulative %/
patient-years
Thromboembolism* 35 (13.1) 1.06
Caged ball 8 (11.3) 0.69
Tilting disc 16 (12.1) 0.92
Bileaflet 11 (18) 2.7
Thrombosis† 18 (6.8) 0.51
Caged ball — 0
Tilting disc 15 (11.4) 0.81
Bileaflet 3 (4.9) 0.66
Nonstructural dysfunction‡ 18 (6.8) 0.52
Caged ball 3 (4.2) 0.25
Tilting disc 14 (10.6) 0.75
Bileaflet 1 (1.6) 0.24
Bleeding 3 (1.1) 0.08
Caged ball — 0
Tilting disc 2 (1.5) 0.1
Bileaflet 1 (1.6) 0.22
Endocarditis 1 (0.4) 0.03
Caged ball — 0
Tilting disc 1 (0.8) 0.054
Bileaflet — 0
Reoperation* 28 (10.6) 0.8
Caged ball 1 (1.4) 0.08
Tilting disc 26 (19.7) 1.4
Bileaflet 1 (1.6) 0.22TABLE 4. Factors significantly associated with late death, thro
Variable modalities Late mortality P value Thr
Valvular disease .039
Stenosis (n  124) 20 (16.1%)
Mixed (n  140) 36 (25.7%)
Previous OMC .014
Yes (n  13) 1 (7.7%)
No (n  251) 55 (21.9%)
Operation era .01
1975-1980 (n  45) 14 (31.1%)
1981-1985 (n  92) 29 (31.5%)
1986-1990 (n  66) 9 (13.6%)
1991-1995 (n  30) 3 (10%)
1996-2002 (n  31) 1 (3.2%)
Prosthesis type .01
Caged ball (n  71) 25 (35.2%)
Tilting disc (n  132) 27 (20.5%)
Bileaflet (n  61) 4 (6.6%)
Postoperative AF* .01
Yes (n  174) 54 (31%)
No (n  90) 2 (2.2%)
Yes No Ye
EF*† (mean  SD): 48.6  6 56.4  7 .01 54 
Categorical data are presented as: conts (percentages). AF, Atrial fibrillation; EF,
s a continuous variable.
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of endocarditis and pannus formation) occurred in 18
(6.8%) patients. Late prosthetic valve endocarditis devel-
oped in 1 patient (0.4%), who successfully underwent re-
operation. Twenty-eight patients (10.6%) underwent reop-
eration for valve-related complications (13 nonstructural
dysfunction, 14 valve thrombosis, and 1 endocarditis), with
2 deaths (in the thrombosis group). Freedom from reopera-
tion at 1, 5, 10, 15, 20, and 25 years was 99.2%  0.005%,
95%  0.014%, 91.6%  0.018%, 88.6%  0.022%, and
85.7%  0.041% (Figure E3), with an incidence of 0.8%
patients per year. The implantation of a tilting disc prosthe-
sis was identified as determinant for reoperation.
Functional Class and Echocardiographic Results
At the end of follow-up, 208 patients (78.8%) were still
alive: 61.1% were in New York Heart Association class I,
33.6% were in class II, and 5.3% were in class III or IV.
Electrocardiographic and echocardiographic examination
results for patients who survived more than 20 years are
reported in Table 6 (n  52). No patient with a bileaflet
device has yet reached such a long follow-up. Atrial fibril-
lation was seen in 46 (88.5%) of 50 patients. The peak
pressure gradients ranged between 6 and 27 mm Hg (mean,
15.2 mm Hg). Atrial enlargement was found in all patients
with a caged ball prosthesis. A stenotic condition with high
gradients was seen in only 1 patient with a caged ball
prosthesis; this patient is currently under evaluation for
reoperation. The left ventricular configuration was normal
in more than 80.8% (42 of 52) of patients. Five (9.6%) of 52
patients had fractional shortening lower than 15%, and 10
(19.2%) of 52 patients had a left ventricular end diastolic
diameter greater than 56 mm.
Pregnancies
There were 48 pregnancies in 37 women. The 2 patients
TABLE 5. Multivariate analysis for late death, reoperation,
and thromboembolic events
Risk factor  HR 95% CI P value
Late death
EF at 12 months .08 0.89 0.88-0.92 .001
Postoperative AF 1.87 6.50 1.52-27.87 .001
Reoperation
Type of prosthesis:
tilting disc
2.8 16.63 2.25-122.8 .004
Thromboembolism
Postoperative AF 2.4 11.27 3.67-34.67 .001
Prosthetic model:
Carbomedics
1.6 4.82 1.45-15.99 .01
AF, Atrial fibrillation; EF, ejection fraction; HR, hazard ratio; CI, confidence
interval.treated with heparin experienced valve thrombosis that ne-
The Journal of Thoraccessitated surgical treatment, and they experienced periop-
erative abortion. With regard to the warfarin-treated subset,
no patient experienced adverse cardiac or valve-related
events during childbearing. There were 27 healthy babies,
16 spontaneous abortions, 2 stillbirths, and 1 embryopathy
(small ventricular septal defect). Table 7 displays significant
results of univariate and multivariate analysis for adverse
fetal outcomes (cumulative mortality and morbidity).
Discussion
Over the last 3 decades, mitral surgery has evolved toward
the tendency to preserve the native valve. In case of infea-
sible valve reconstruction, our practice has evolved from
predominant implantation of bioprosthetic devices in the
early 1970s to prevalent adoption of mechanical devices
from the early 1980s on. Routine attempts to preserve the
mitral chordae have been made since the early 1990s. The
TABLE 6. Echocardiographic and clinical examination at
rest in patients with more than 20 years of follow-up
Variable
Caged ball
(n  27)
Tilting disc
(n  25)
Atrial enlargement (40 mm) 27 (100%) 21 (84%)
LV dilatation (56 mm) 6 (22.2%) 4 (16%)
Fractional shortening 15% 3 (11.1%) 2 (8%)
Atrial fibrillation 26 (96.3%) 20 (80%)
NYHA class (III-IV) 3 (11.1%) 2 (8%)
Categorical data are presented as: conts (percentages). LV, Left ventricle;
NYHA, New York Heart Association.
TABLE 7. Univariate and multivariate analysis of preg-
nancy outcomes
Variable
No adverse
fetal events
Adverse fetal
events P value
Mean INR 2.6  0.3 2.4  0.1 .001
Mean warfarin dose 4.8  1.4 7.3  1.6 .001
Warfarin dose (mg/d) .001
5 4 (19%) 17 (85.2%)
5 23 (81%) 2 (8%)
Order of pregnancy
First 25 (71.4%) 10 (28.6%) .003
Subsequent 2 (18.2%) 9 (81.8%)
Exact logistic regression
model covariate* 
OR
(exact 95% CI) P value
Warfarin dose 5 vs
5 mg
3.7 41.7 (5.8-298.4) .001
Subsequent vs first
pregnancy
.21 0.75 (0.25-6.2) .65
Categorical data are presented as: conts (percentages). No significant differ-
ence was found for maternal age and prosthetic model. INR, International
normalized ratio; OR, odds ratio; CI, confidence interval. *r2  0.687.
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is still controversial,2,3 and, in particular, severe mitral
stenosis and mixed mitral disease yield the worst long-term
results in terms of freedom from reoperation.7,8 Conversely,
the quest for the ideal replacement device for young women
of childbearing age remains open.
The young rheumatic population, free from significant
comorbidities, provides a good model for purely assessing
valve performance over the long term.9 The most important
findings of this study were as follows: (1) more than 56% of
the fatal events were due to worsening cardiac function; (2)
in long-term follow-up, mechanical prostheses imply ac-
ceptable complication rates; and (3) warfarin therapy during
pregnancy allows virtually no maternal events and predict-
able fetal complications.
The evidence that the determinants of long-term survival
are chronic atrial fibrillation and early postoperative left
ventricular performance confirms the already stressed need
for early surgical treatment10,11 and favors the preservation
of the subvalvular apparatus and concomitant operation for
atrial fibrillation. Freedom from thromboembolism in this
study seems superior to that reported elsewhere.12-14 Two
major reasons for this low complication rate may be the
mean age of the patients (younger than that reported in most
series) and the close anticoagulation follow-up, coupled
with the compliance of the patient population. The literature
has not yet provided any appropriate evidence to determine
whether the advancements in prosthesis design have led to
a reduction in thromboembolic and hemorrhagic risk. Mur-
day and colleagues11 have performed the only prospective
randomized trial comparing the St Jude Medical and the
Starr-Edwards prostheses in the English literature, and they
reported similar thromboembolism and antithrombotic hem-
orrhage rates with the 2 prostheses. Notably, these results
were achieved with a target INR of 3.0 to 4.0 with both
valve types. Jamieson and coworkers13 reported a linearized
rate of thromboembolism as high as 5% per patient-year
with bileaflet devices under lower INR ranges, and similar
outcomes were reported by others.15,16 In this series, the
higher rates of thromboembolism in the bileaflet group may
be partly explained by the lower-intensity anticoagulation
protocol and by the higher incidence of sudden deaths in the
tilting disc and caged ball groups; this may have masked the
real incidence in these patient subsets. It is noteworthy that
in multivariate analysis, the bileaflet model was not an
independent predictor of thromboembolism. Again, postop-
erative atrial fibrillation was a strong risk factor. The finding
that most of the events in the bileaflet group occurred in
patients with a Carbomedics device is consistent with pub-
lished data. Nevertheless, comparative studies with other
third-generation devices failed to confirm such evi-
dence.10-14
18 The Journal of Thoracic and Cardiovascular Surgery ● July 2Overall freedom from reoperation proved satisfying and
far better than that reported with bioprostheses or mitral
repair.12,17,18 Tilting disc devices showed the highest rate of
nonstructural dysfunction (namely, pannus formation), in
accordance with larger series.14
Anticoagulant management of pregnant women with me-
chanical heart valves is still troublesome. No controlled
clinical trial has yet demonstrated which is the safest regi-
men for the mother and the baby.19 The special management
protocol of patients with prosthetic heart valves undergoing
pregnancy at our institution has already been published4,5
and also incorporated in a recent clinician update.20 Me-
chanical mitral replacement allows favorable maternal and
fetal outcomes, especially in women affected by mitral
stenosis.21 Our data showed that in this setting, the occur-
rence of pregnancy does not increase the risk of valve-
related complications; fetal events remain within an accept-
able range unless the mean warfarin daily dose required to
maintain a therapeutic INR exceeds 5 mg. The mean annual
rate of spontaneous abortions observed in this series ap-
proached 12.9‰ and it is worth reporting that, as issued by
the Ministry of Health, the mean annual rate in the Italian
population is 4.4‰ (ranging from 0.8‰ to 8.5‰ according
to maternal age). Comparisons with pregnancy outcomes
and maternal events both in women with untreated rheu-
matic disease and in those with biologic devices or percu-
taneous mitral plasty may provide more insights on these
results.21,22 It is worthy of mention that a previous study
from our group could not find any correlation between
prosthetic type and pregnancy outcome.5
Limitations of the Study
Being retrospective, this study could have implied some
incompleteness of information. This is particularly true for
the incidence of thromboembolism, which might have been
the most frequent cause of sudden unexplained deaths in the
caged ball and tilting disc prosthesis groups, and, therefore,
the rate of such complications in survivors would be lower.
Similarly, because of the retrospective design, no analysis
was performed of the adequacy of anticoagulation in the
overall population and, in particular, in the subgroups of
patients experiencing thrombosis, thromboembolism, or
bleeding events. The long-term retrospective design, even
on a specific patient population, might have affected the
comparison between different devices. Indeed, different
preoperative conditions, management strategies, and
follow-up times somehow weakened the study results.
Conclusions
Mechanical prostheses in young women provide gratifying
long-term survival and freedom from valve-related morbid-
ity, though inherent patient and study characteristics have to
be considered when evaluating these outcomes. No type of
005
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CDprosthesis has so far shown a significant superiority in terms
of survival, although a better trend was observed with
bileaflet models. Unless a longer follow-up period (15
years) and a larger series of bileaflet devices will allow
confirmation of this trend, the preference of 1 type of
prosthesis over another in this subset of patients will not be
supported by clinical evidence of greater appropriateness.
The prognostic role of left ventricular function and atrial
fibrillation overwhelmed any differences between prosthetic
designs and with regard to thromboembolism. Pregnancies
can be undergone with very low maternal risk.
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Appendix 1: Variables Tested at Univariate Analysis
and Included in the Multivariate Models Predicting
Late Death, Reoperation, and Thromboembolic
Events
● Age
● Mitral valve disease (stenosis/mixed)
● Preoperative New York Heart Association class (I-II/III-IV)
● Previous open mitral commissurotomy (yes/no)
● Emergency operation (yes/no)
● Operation era (1975-1980/1981-1985/1986-1990/1991-
1995/1996-2002)
● Prosthesis type (caged ball/tilting disc/bileaflet)
● Prosthetic model: Starr-Edwards (yes/no); Sorin standard
(yes/no); Sorin Carbocast (yes/no); Björk-Shiley (yes/no);
other tilting disc models (models implanted in 5% of
patients each), including Sorin All Carbon, Lillehei-Kaster,
and Medtronic-Hall (yes/no); Sorin Bicarbon (yes/no); Car-
bomedics (yes/no); or other bileaflet models (models im-
planted in 5% of patients each), including St Jude Medi-
cal, Edwards Tekna, and Edwards Mira (yes/no)
● Postoperative atrial fibrillation (yes/no)
● Ejection fraction
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